eMedicine Specialties > Endocrinology > Metabolic Disorders

Lipodystrophy, Acquired Partial: Follow-up

Author: George T Griffing, MD, Professor of Medicine, St Louis University School of Medicine
Coauthor(s): Robert A Gabbay, MD, PhD, Associate Professor of Medicine, Division of Endocrinology, Diabetes and Metabolism, Laurence M Demers Career Development Professor, Penn State College of Medicine; Director, Diabetes Program, Penn State Milton S Hershey Medical Center; Executive Director, Penn State Institute for Diabetes and Obesity
Contributor Information and Disclosures

Updated: Jun 18, 2008

Follow-up

Complications

The most significant complications are disfigurement in severe facial involvement, renal disease, and, rarely, insulin resistance state.

Prognosis

Acquired partial lipodystrophy is a slowly progressive disease. In the absence of associated renal impairment or insulin resistance, the prognosis is excellent.

Patient Education

  • Educating patients about the disease and its associated complications is very important.
  • Parents should be notified about facial changes that may occur in their child; they should also be told about the importance of balancing dietary intake in order to avoid metabolic complications and to ensure healthy development.

Miscellaneous

Medicolegal Pitfalls

These can result from failure to educate patients about the disease and its associated complications.

 
Acknowledgments

eMedicine extends its thanks to Irina Lendel, MD, Clinical Instructor in Endocrinology, Division of Endocrinology, Diabetes, and Metabolism, Milton S Hershey Medical Center and Waleed Aldhahi, MD, FRCPC, Clinical Research Fellow, Department of Endocrinology, Joslin Diabetes Center, Harvard University for previous versions of this article.



More on Lipodystrophy, Acquired Partial

Overview: Lipodystrophy, Acquired Partial
Differential Diagnoses & Workup: Lipodystrophy, Acquired Partial
Treatment & Medication: Lipodystrophy, Acquired Partial
Follow-up: Lipodystrophy, Acquired Partial
Multimedia: Lipodystrophy, Acquired Partial
References
[ CLOSE WINDOW ]

References

  1. Mitchell SW. Singular case of absence of adipose matter in the upper half of the body. Am J Med Sci. 1885;90:105-6.

  2. Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore). Jan 2004;83(1):18-34. [Medline].

  3. Cronin CC, Higgins TJ, Molloy M. Lupus, C3 nephritic factor and partial lipodystrophy. QJM. Apr 1995;88(4):298-9. [Medline].

  4. Walport MJ, Davies KA, Botto M, et al. C3 nephritic factor and SLE: report of four cases and review of the literature. QJM. Oct 1994;87(10):609-15. [Medline].

  5. Walker PD. Dense deposit disease: new insights. Curr Opin Nephrol Hypertens. May 2007;16(3):204-12. [Medline].

  6. Caramaschi P, Biasi D, Lestani M, et al. A case of acquired partial lipodystrophy associated with POEMS syndrome. Rheumatology (Oxford). Mar 2003;42(3):488-90. [Medline]. [Full Text].

  7. Sissons JG, West RJ, Fallows J, et al. The complement abnormalities of lipodystrophy. N Engl J Med. Feb 26 1976;294(9):461-5. [Medline].

  8. Hegele RA, Cao H, Liu DM, et al. Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy. Am J Hum Genet. Aug 2006;79(2):383-9. [Medline]. [Full Text].

  9. Hegele RA, Joy TR, Al-Attar SA, et al. Thematic review series: adipocyte biology. Lipodystrophies: windows on adipose biology and metabolism. J Lipid Res. Jul 2007;48(7):1433-44. [Medline]. [Full Text].

  10. Demetriou K, Kallikas I, Zouvani I, et al. The pregnant patient with partial lipodystrophy developing acute renal failure--onset of de novo membranoproliferative glomerulonephritis. Nephrol Dial Transplant. Aug 1998;13(8):2121-4. [Medline]. [Full Text].

  11. Meyrier A. The patient with glomerulonephritis and lipodystrophy. Nephrol Dial Transplant. Jan 1997;12(1):226-7. [Medline]. [Full Text].

  12. Chopra S, Isaacs R, Mammen K, et al. Renal transplantation in a patient with Barraquer-Simons disease and mesangiocapillary glomerulonephritis type II. Nephrol Dial Transplant. Oct 2000;15(10):1723-4. [Medline]. [Full Text].

  13. Garg A. Lipodystrophies. Am J Med. Feb 2000;108(2):143-52. [Medline].

  14. Al-Attar SA, Pollex RL, Robinson JF, et al. Quantitative and qualitative differences in subcutaneous adipose tissue stores across lipodystrophy types shown by magnetic resonance imaging. BMC Med Imaging. 2007;7:3. [Medline]. [Full Text].

  15. Pujol RM, Domingo P, Xavier-Matias-Guiu, et al. HIV-1 protease inhibitor-associated partial lipodystrophy: clinicopathologic review of 14 cases. J Am Acad Dermatol. Feb 2000;42(2 Pt 1):193-8. [Medline].

  16. Guettier JM, Park JY, Cochran EK, et al. Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation. Clin Endocrinol (Oxf). Apr 2008;68(4):547-54. [Medline].

  17. Walker UA, Kirschfink M, Peter HH. Improvement of acquired partial lipodystrophy with rosiglitazone despite ongoing complement activation. Rheumatology (Oxford). Feb 2003;42(2):393-4. [Medline]. [Full Text].

  18. [Best Evidence] Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. Jun 14 2007;356(24):2457-71. [Medline]. [Full Text].

  19. Aragona P, Quattrocchi P, Trombetta CJ, et al. Retinal alterations in acquired partial lipodystrophy: a case report. Arch Ophthalmol. Feb 2002;120(2):218-20. [Medline].

  20. Biasi D, Caramaschi P, Carletto A, et al. A case of acquired partial lipodystrophy associated with localized scleroderma and undifferentiated connective tissue disease. Rheumatol Int. 1999;19(1-2):75-6. [Medline].

  21. Dupéré A, Poulin Y. Facial lipoatrophy following systemic lupus erythematosus. J Cutan Med Surg. May-Jun 2003;7(3):232-5. [Medline].

  22. Haque WA, Shimomura I, Matsuzawa Y, et al. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab. May 2002;87(5):2395. [Medline]. [Full Text].

  23. Hisamichi K, Suga Y, Hashimoto Y, et al. Two Japanese cases of localized involutional lipoatrophy. Int J Dermatol. Mar 2002;41(3):176-7. [Medline].

  24. Orrell RW, Peatfield RC, Collins CE, et al. Myopathy in acquired partial lipodystrophy. Clin Neurol Neurosurg. May 1995;97(2):181-6. [Medline].

  25. Patel D, Page B. Ocular complications in acquired partial lipodystrophy. Postgrad Med J. Nov 2006;82(973):774. [Medline].

  26. Poley JR, Stickler GB. Progressive lipodystrophy. A clinical study of 50 patients. Am J Dis Child. Oct 1963;106:356-63. [Medline].

  27. Porter WM, O'Gorman-Lalor O, Lane RJ, et al. Barraquer-Simons lipodystrophy, Raynaud's phenomenon and cutaneous vasculitis. Clin Exp Dermatol. Jun 2000;25(4):277-80. [Medline].

  28. Winhoven SM, Hafejee A, Coulson IH. An unusual case of an acquired acral partial lipodystrophy (Barraquer-Simons syndrome) in a patient with extrinsic allergic alveolitis. Clin Exp Dermatol. Jul 2006;31(4):594-6. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

Barraquer-Simons syndrome, Barraquer disease, Simons disease, cephalothoracic lipodystrophy, acquired partial lipodystrophy, fat loss, fat hypertrophy, adipocyte lysis, lipohypertrophy, mesangiocapillary glomerulonephritis, membranoproliferative glomerulonephritis, systemic lupus erythematosus, SLE, dermatomyositis, hypothyroidism, pernicious anemia, PA, celiac disease, dermatitis herpetiformis, rheumatoid arthritis, RA, temporal arteritis, leukocytoclastic vasculitis, complement anomaly, complement abnormality, autoimmune process, autoimmune disease

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

George T Griffing, MD, Professor of Medicine, St Louis University School of Medicine
George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physician Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical Research, Endocrine Society, International Society for Clinical Densitometry, and Southern Society for Clinical Investigation
Disclosure: Nothing to disclose.

Coauthor(s)

Robert A Gabbay, MD, PhD, Associate Professor of Medicine, Division of Endocrinology, Diabetes and Metabolism, Laurence M Demers Career Development Professor, Penn State College of Medicine; Director, Diabetes Program, Penn State Milton S Hershey Medical Center; Executive Director, Penn State Institute for Diabetes and Obesity
Robert A Gabbay, MD, PhD is a member of the following medical societies: American Association of Clinical Endocrinologists, American Diabetes Association, and Endocrine Society
Disclosure: Novo Nordisk Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching

Medical Editor

Amir E Harari, MD, Staff Physician, Endocrinology Division, Instructor, Department of Clinical Medicine, Naval Medical Center at San Diego
Amir E Harari, MD is a member of the following medical societies: Alpha Omega Alpha, American Association of Clinical Endocrinologists, American College of Physicians, and Endocrine Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Arthur B Chausmer, MD, PhD, FACP, FACE, FACN, CNS, Professor of Medicine (Endocrinology, Adj), Johns Hopkins School of Medicine; Affiliate Research Professor, Bioinformatics and Computational Biology Program, School of Computational Sciences, George Mason University; Principal, C/A Informatics, LLC
Arthur B Chausmer, MD, PhD, FACP, FACE, FACN, CNS is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Endocrinology, American College of Nutrition, American College of Physician Executives, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Informatics Association, American Society for Bone and Mineral Research, American Society of Law Medicine and Ethics, Endocrine Society, and International Society for Clinical Densitometry
Disclosure: Nothing to disclose.

CME Editor

Mark Cooper, MBBS, PhD, FRACP, Head, Diabetes & Metabolism Division, Baker Heart Research Institute, Professor of Medicine, Monash University
Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD, Professor of Medicine, St Louis University School of Medicine
George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physician Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical Research, Endocrine Society, International Society for Clinical Densitometry, and Southern Society for Clinical Investigation
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.